Clinical outcomes of tocilizumab therapy in polyarticular and systemic juvenile idiopathic arthritis: a single-center...

Area of Science:

• Pediatric Rheumatology
• Immunology
• Pharmacology

Background:

• Juvenile Idiopathic Arthritis (JIA) encompasses several chronic autoimmune conditions affecting children.
• Treatment resistance to conventional disease-modifying antirheumatic drugs (DMARDs) and biological agents (bDMARDs) necessitates exploring alternative therapies.
• Tocilizumab (TOC), an interleukin-6 receptor inhibitor, has shown promise in adult autoimmune diseases.

Purpose of the Study:

• To evaluate the safety and efficacy of Tocilizumab (TOC) in pediatric patients diagnosed with polyarticular (pJIA) and systemic (sJIA) juvenile idiopathic arthritis.
• To assess TOC's impact on disease activity markers, clinical outcomes, and adverse events in a cohort of JIA patients.
• To determine TOC's potential steroid-sparing effect in managing JIA.

Main Methods:

• A retrospective, single-center study involving 29 pediatric JIA patients (13 sJIA, 16 pJIA) treated with TOC for 24 months.
• Data collection included medical records, laboratory tests (CRP, ESR, WBC), and Juvenile Disease Activity Score (JADAS71) at baseline and follow-up intervals.
• Safety assessments focused on adverse events, including infections and macrophage activation syndrome (MAS).

Main Results:

• Significant reductions in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were observed within three months of TOC initiation.
• Sustained improvement in JADAS71 scores was noted over the 24-month treatment period.
• 73.07% of patients achieved inactive disease or low disease activity, with manageable adverse events (mild-to-moderate infections) and no serious adverse events or MAS. A notable steroid-sparing effect was observed.

Conclusions:

• Tocilizumab (TOC) demonstrates significant efficacy in reducing disease activity and improving clinical outcomes for children with pJIA and sJIA.
• TOC exhibits a favorable safety profile in this pediatric cohort, with manageable adverse events.
• Tocilizumab is a valuable therapeutic option for JIA, contributing to improved disease management and quality of life, and offers a steroid-sparing benefit.